Tag: pharmaceuticals

The Chinese pharmaceutical distributor prices at the top to raise $1.13 billion after attracting $110 billion worth of orders. Separately, Digital China raises $49 million from ... Japanese firm Taisho Pharmaceutical pays $310 million for six Asia-Pacific brands and the Indonesian business of Bristol-Myers, as it seeks to build its presence in the OTC ... The Chinese distributor of pharmaceutical products will be the first company to take orders for a Hong Kong listing after the summer and has set the price range at HK12.25 to ... Hisamitsu becomes the fourth Japanese pharmaceutical company to announce a US acquisition in the recent past, as it makes a tender offer for transdermal and women's health ... The prescription drug firm buys specialised US company Sciele in the fourth Japanese outbound pharmaceutical deal in less than a year. Institutional investors get 70% of the $105 million offering from the Chinese drug maker. Retail subscriptions are less overwhelming. IPO investors will need to weigh up United Laboratories' strong structural growth potential and generous valuation against a regulated market with plenty of competition and ... The pharmaceutical company trades up 5.5% after pricing its $226.5 million IPO at the top of the range. Sterling Biotech prices wide after demand is described as healthy but price sensitive. The Chinese medicine maker becomes the first Mainland company to cut the size of a US offering this year as the fall-out from the equity market correction broadens. The company banks on an ageing Chinese population and higher urban wealth to drive growth of its key drug. A hefty increase in the deal size and concern about the use of proceeds push the bond price sharply below par. Orchid Chemicals raises $175 million to grow its portfolio of drugs. Conversion premium set at 30%. The first two Hong Kong IPOs of size this year raise $255 million between them. Retail demand remains strong, triggering full clawbacks on both deals. Hong Kong companies Wuyi Pharmaceutical and Meadville seek to raise a combined $265 million with trading debuts scheduled for the first two days of February. Merrill Lynch finds a foreign buyer for the Australian cancer drug specialist. Issue marks seventh CB from an Indian pharmaceutical company since December; conversion premiums still high. Strong expansion story allows company to fix conversion price on 25% of the deal in 12 months time; investors compensated by high yield and high bond floor.